Pfizer targets obesity with new once-daily Danuglipron drug

(NEW YORK) -- Pfizer announced early Thursday morning that it has selected its preferred once-daily modified release formulation of danuglipron, a move that it said was a significant milestone in the obesity drug’s development.Danuglipron, an oral glucagon-like peptide-1 (GLP-1) receptor agonist, will undergo dose... Read More.